Skip to main content
. 2023 Oct 6;34(11):1889–1899. doi: 10.1681/ASN.0000000000000219

Figure 2.

Figure 2

The presence of an allele p.N264K in patients with APOL1 HR group (homozygous for G1 or G2 or compound heterozygous for G1/G2) mitigates the risk of CKD and ESKD among MVP participants to values similar to those of participants in the APOL1 low-risk group. All OR are relative to the reference and reported as OR (95% CI). Reference group: APOL1 low-risk genotype, and N264K− APOL1 HR refers to two copies of the APOL1 HR variants G1 or G2 or G1 and G2. APOL1 LR, 0 or 1 total copy of the G1 or G2 HR variant. N264K+, carrying 1 or 2 copies of APOL1 N264K. N264K−, carrying 0 copies of APOL1 N264K. Logistic regression was used to evaluate the association of APOL1 HR and p.N264K allele genotype and CKD (A) and ESKD (B). ORs were adjusted for age, sex, ten principal components of ancestry, BMI, hypertension, and renin–angiotensin–aldosterone system blockade. Minimally adjusted models are presented in Supplemental Table 2. BMI, body mass index.